By InvitationNot Applicable

Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).

Russia1,000 participantsStarted 2025-08-14

Plain-language summary

Systemic mediastinal lymph node dissection is a standard step in radical surgery for advanced non-small cell lung cancer (NSCLC). However, it does not carry the risks associated with certain procedures (chylothorax, recurrent nerve palsy, diaphragmatic relaxation, intrapleural hemorrhage, injury to other chest organs (esophagus, great vessels), etc.). Data on their incidence and predictors in routine practice are limited. Objective: To assess trends and characteristics of projects directly related to Lymph Node Dissection and to identify independent risk factors for their development.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years. * Clinical stage IA-IIIB NSCLC (TNM 8th edition), oncologically radical resection is planned: anatomical segmentectomy/lobectomy/bilobectomy/pneumonectomy (including sleeve resection). * LND (systematic) is performed with mandatory inclusion of group 7 (subcarinal) lymph nodes. * Signed informed consent from all study patients. Exclusion Criteria: * Small cell lung cancer, benign and metastatic tumors. * "Wedge" surgery without any lymph node dissection. * Nonemergency surgery; conversion is acceptable. * Patients who cannot complete 30 days of observation (no contact, etc.) should be excluded prior to surgery.

What they're measuring

Frequency and outcome after Lymphadenectomy complications within 30 days after surgery

Timeframe: 30 days

Trial details

NCT IDNCT07401498

SponsorRegional Clinical Oncology Dispensary

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2026-08

View on ClinicalTrials.gov More Lymph Node Dissection trials